Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCorRxBICX -10.71%40 Debt-to-Equity is -0.19 as of Mar. 2026. GuruFocus rates BICX with a GF Score™ of 40/100 and a GF Value™ of $2.79 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 557 Healthcare Providers & Services companies, BioCorRx ranks worse than 179533.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioCorRx's Debt-to-Equity or its related term are showing as below:
BICX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.68 Med: -0.23 Max: 6.65
Current: -0.19
During the past 13 years, the highest Debt-to-Equity Ratio of BioCorRx was 6.65. The lowest was -1.68. And the median was -0.23.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BioCorRx Debt-to-Equity Related Terms
BioCorRx Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BioCorRx's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BICX vs BMGL, HLYK, SYRA: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, BioCorRx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCorRx Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioCorRx's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCorRx (BICX) has a Debt-to-Equity of -0.19 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioCorRx and its competitors. According to the industry distribution chart, BioCorRx ranks #999999 out of 557 companies in the Healthcare Providers & Services industry.
Is BioCorRx's Debt-to-Equity too high?
BioCorRx's current Debt-to-Equity is -0.19. Based on the distribution chart, BioCorRx ranks #999999 out of 557 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioCorRx has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioCorRx's Debt-to-Equity compare to BMGL and HLYK?
According to the Healthcare Providers & Services industry distribution chart, BioCorRx ranks #999999 out of 557 companies for Debt-to-Equity. This places BioCorRx in the lower half of its industry. The industry median Debt-to-Equity is 0.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BioCorRx and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCorRx's current Debt-to-Equity is -0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCorRx stock overvalued right now?
Based on GuruFocus' analysis, BioCorRx (BICX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.79, compared to a current price of $0.25 — trading 91% below its estimated fair value. The current Debt-to-Equity is -0.19. BioCorRx's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BioCorRx (BICX), the current Debt-to-Equity is -0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCorRx (BICX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCorRx stock appears to be undervalued.
The current stock price of $0.25 is trading 91% below its estimated GF Value™ of $2.79.
GuruFocus considers BioCorRx to be Possible Value Trap.
Key valuation signals for BICX:
Debt-to-Equity: -0.19
GF Value™: $2.79 vs. price of $0.25 (91% below fair value)
No single metric tells the full story. See the BICX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCorRx Inc through its subsidiaries, develops and provides addiction treatment solutions, offering an approach to the treatment of substance use and other related disorders. The company makes the Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program available to healthcare providers to utilize when the healthcare provider determines it is medically appropriate and indicated for their patients. Its products include BICX102 and BICX104. It operates in a single segment.
40GF Score
Get the complete analysis for BICX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BICX has been successfully added to your 
